http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20120021854-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_755bf4e37e2e5ca68ee4d1c3a493e6da http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a125b986ec963ee7a695ccbb814538c9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-5434 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36 |
| filingDate | 2010-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87a80fda97c84a703d46bafea3eaaa40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed04beba516dbded7e29cb2dfa606b03 |
| publicationDate | 2012-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20120021854-A |
| titleOfInvention | Actinomycetem mitosis immune stimulating factor IST recombination protein having efficacy of bacteria-derived cancer vaccine adjuvant and method for preparing same |
| abstract | The present invention relates to an immunostimulating factor (ISTF) recombinant protein having a potency of the A. actinomycetemcomitans bacteria-derived cancer vaccine adjuvant, and a method for preparing the same. More specifically, the present invention relates to Actinobacillus actinomycetemcomitans, a major pathogenic bacterium of periodontal disease. ISTF protein, a new immunologically active substance that exhibits nonspecific and potent immunoactivity, was identified as an omp-1 like protein of A. actinomycetemcomitans through the gene identification process, B cell, macrophage and dendritic cell. In addition to showing strong immune activity against immune cells, including antigen-presenting cells such as DC (dendirtic cells), when only dendritic cells treated with ISTF protein were treated from animal models with tumor formation, only untreated dendritic cells Much better antitumor effect than when administered As a vaccine for cancer vaccine using ISTF protein isolated from A. actinomycetemcomitans bacteria, it is provided as a biological medicine material and manufactured for mass production of these ISTF recombinant proteins to expand the industrial scope through their high value products. It is about a method. |
| priorityDate | 2010-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 283.